Alterity Therapeutics Secures FDA CMC Alignment for ATH434 Phase 3 Program
Alterity Therapeutics received positive FDA feedback on chemistry, manufacturing and control elements of its ATH434 Phase 3 development program during a second Type C meeting. Manufacturing scale-up is advancing in parallel and the End-of-Phase 2 meeting with the FDA remains on track for mid-2026.
1. FDA Feedback on Phase 3 CMC
Alterity achieved alignment with the FDA on chemistry, manufacturing and control (CMC) aspects of its ATH434 Phase 3 program for Multiple System Atrophy in a second Type C meeting. The FDA’s positive written feedback supports the company’s plans for pivotal trial initiation and eventual commercialization.
2. Manufacturing Scale-Up Progress
In parallel with regulatory engagement, Alterity is scaling up manufacturing processes for ATH434, validating production workflows and quality control protocols. These efforts aim to ensure sufficient supply for both clinical trial use and potential market launch.
3. Milestones and Next Steps
Alterity remains on schedule for an End-of-Phase 2 FDA meeting in mid-2026 to finalize clinical development strategies. Following that meeting, the company plans to initiate its Phase 3 pivotal trial in MSA, advancing toward potential approval.